Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
May 18, 2011
Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
Two genomic tests for cancer risk recurrence -- Oncotype DX and PAM50 -- show reasonable agreement on high- and low-risk categories but do not agree in their classification of intermediate-risk patients, according to a recent comparison of the assays.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Oncotype DX Study Raises Questions About RT-PCR Testing for HER2 Expression
December 1, 2011 / PCR Insider - Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter - NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX
December 14, 2011 / Pharmacogenomics Reporter - St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter